Zealand Pharma A/S (ZEAL.CO)
| Previous close | 221.20 |
| Open | 222.60 |
| Bid | 224.40 x 0 |
| Ask | 224.20 x 0 |
| Day's range | 220.20 - 225.80 |
| 52-week range | 69.55 - 228.00 |
| Volume | |
| Avg. volume | 173,692 |
| Market cap | 11.508B |
| Beta (5Y monthly) | 0.97 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -23.13 |
| Earnings date | 08 Mar 2023 - 13 Mar 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 243.75 |
- GlobeNewswire
Total number of shares and voting rights in Zealand Pharma at December 30, 2022
Company announcement – No. 58 / 2022 Total number of shares and voting rights in Zealand Pharma at December 30, 2022 Copenhagen, Denmark and Boston, MA, U.S. December 30, 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Compa
- GlobeNewswire
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
Company announcement – No. 57 / 2022 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark and Boston, MA, U.S. December 8, 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 64,919 divided into 64,919 new shares with a nominal value of
- GlobeNewswire
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Company announcement – No. 56/ 2022 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark and Boston, MA, U.S. December 2, 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand's share
